Home
overview

SMi's Superbugs & Superdrugs Conference is now in it's 13th year.

Visit the 2011 event page

 


 
2007 Past Event Details:

 

 

*****REGISTER NOW ONLY 9 PLACES LEFT*****

Enjoyed the crisp, relevant conference on Anti-bacterials”
Sudha Ravishanker, Research Scientist, AstraZeneca

Antimicrobial resistance is continuously growing whilst the number of new drugs being developed and reaching the market are few, to say the least. Everyday, we hear news of new superbugs hitting the global community. This problem demands a fresh approach to combating resistance. So why does the pharmaceutical industry show so little interest in developing new antibiotics?

SMi’s Superbugs & Superdrugs; A focus on antimicrobials will tackle the key issues in antimicrobial resistance. We will examine the complex procedures for getting drugs through regulatory hurdles taking into account the difference in requirements in the US and EU. Dive into the R&D pipeline and inspect the novel advances in drug development.

Do not miss this opportunity to find out the incentives for development and learn of the advances in the pipeline for both anti-bacterials & anti-fungals.

Hear international case studies and expert opinions from leaders in the field, including:

  • Dr Kenneth Tack, Executive Director, Pfizer
  • Dr Tom P Gootz, Senior Research Fellow, Department of Antibiotics, Immunology and Cancer, Pfizer
  • Dr Neil S Ryder, Executive Director, Infectious Diseases, Novartis Institutes for Biomedical Research
  • Jeff Hermes, Senior Director Microbil Biochemistry, Merck Research Laboratories
  • Dr PJ Turner, Associate Director, Infection Discovery, AstraZeneca
  • Dr E David G McIntosh, Medical Director Infectious Diseases, Wyeth Europa
  • Dr Ron Van Amsterdam, Senior Clinical Research Manager, Astellas Pharma Europe
  • Dr Dieter Haebich, Director, Medicinal Chemistry, Bayer
  • Soren Kjaerulff, Director, Antimicrobial Peptides, Molecular Biotechnology, R&D, Novozymes
  • Dr Joyce Sutcliffe, Chief Research Scientist, Rib-X Pharmaceuticals
  • Dr Nachum Kaplan, Vice President, Microbiology, Affinium Pharmaceuticals
  • Nafsika Georgopapadakou, Vice President, Infectious Diseases, MethylGene
  • Dr Lloyd Czaplewski, Director of Research, Prolysis Ltd
  • Prof. Malcolm G. P. Page, Head of Biology, Basilea Pharmaceutica
  • William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals
  • Dr Stephen Hawser, Director of Microbiology, Arpida
  • John Powers, MD, National Institute of Health
  • Mair Powell, Medical Assessor, Licensing Division, MHRA

Chaired by:

Professor Ian Chopra, Professor of Microbiology, Institute of Molecular & Cellular Biology University of Leeds

WHO SHOULD ATTEND SUPERBUGS & SUPERDRUGS?

You should attend this conference if you are an Executive, Director, Chemist or Scientist working in the pharmaceutical or biotech industries within:

 

  • Microbiology
  • Antibiotics
  • Immunology
  • Infection Discovery
  • Infectious Diseases
  • Drug evaluation
  • Medicinal Chemistry
  • Molecular Biotechnology
  • Clinical Pharmacology
  • Drug Development
  • Drug Discovery
  • Project Management
  • New Product Development
  • Preclinical Development
  • Scientific Affairs
  • Portfolio Management
  • Licensing

 

 

WHO WILL YOU MEET AT SUPERBUGS & SUPERDRUGS?

 

 

 

 

 

A sample of the companies already in attendance includes:

 

  • Abingworth Management
  • Achaogen
  • Affinium Pharmaceuticals
  • Anacor Pharmaceuticals
  • Arpida
  • Astellas Pharma
  • AstraZeneca
  • Basilea Pharmaceutica
  • Bayer Healthcare
  • Bioniche Life Sciences
  • CRS Clinical Research Services Andernach
  • Cubist Pharmaceuticals
  • Cumbre
  • European Medicines Agency (E M E A)
  • GlaxoSmithKline
  • Merck
  • MethylGene
  • Mutabilis
  • Mutabilis
  • National Institute of Health
  • Novartis
  • Novozymes
  • Pfizer
  • Prolysis
  • Rib - X - Pharmaceuticals
  • Targanta Therapeutics
  • University Medical Centre Utrecht
  • Wood Mackenzie
  • Wyeth
 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Professor Ian Chopra

Professor Ian Chopra, Professor of Microbiology, Institute of Molecular & Cellular Biology, University of Leeds

9:10 KEYNOTE PRESENTATION

Dr Kenneth Tack

Dr Kenneth Tack, Executive Director, Pfizer

  • The shape of current and future markets
    Current position
    The need for new antibiotics
    Antibiotic research
    Developments in antimicrobial agents
    Problems and solutions
    Where next?
  • 9:50 GUIDANCE TO THE INDUSTRY

    John Powers

    John Powers, MD, National Institute of Health

  • Points to remember
  • Increasing the efficiency in clinical trials
  • Antibiotic resistance and incentives for development
  • 10:30 THE REGULATORY ENVIRONMENT

    Dr Mair Powell

    Dr Mair Powell, Medical Assessor, Licensing Division, , MHRA

  • Requirements and expectations
  • Processes that might facilitate drug development
  • Examining the regulations
  • 11:10 Morning Coffee

    11:30 MULTI-DRUG RESISTANCE IN KLEBSIELLA PNEUMONIAE

    Thomas Gootz

    Thomas Gootz, Senior Research Fellow, Pfizer

  • Carbapenem-resistant K. pneumoniae encoding KPC-2 or KPC-3 enzymes are endemic in some hospitals in NYC
  • Down-regulation of the phosphate porin PhoE in K. pneumoniae leading to carbapenem resistance has only recently been described
  • Very few alternative antibiotics with activity against such multi-resistant Klebsiella are available
  • Klebsiella is more commonly isolated in human infections than Pseudomonas aeruginosa or Acinetobacter
  • Mult-resistant Klebsiella may represent one of the biggest problems in nosocomial infections in the future
  • 12:10 NEW AND NOVEL ADVANCES IN DRUG DEVELOPMENT

    Dr Nachum Kaplan

    Dr Nachum Kaplan, Vice President, Microbiology, Affinium Pharmaceuticals

  • New class of antibacterials
  • Specific-spectrum agent
  • Highly potent against all known MRSA phenotypes
  • Proven efficacious in animal models
  • Orally bioavailable in humans (microdosing)
  • In development as novel iv/oral MRSA agent
  • 12:50 Networking Lunch

    13:50 ANTI-INFECTIVES IN THE DEVELOPMENT PIPELINE, PHASE 2 & PHASE 3

    Dr PJ Turner

    Dr PJ Turner, Associate Director, Infection Discovery, AstraZeneca R&D

  • Anti-Gram-positive agents
  • Anti-Gram-negatives
  • Broad spectrum
  • Anti-fungals
  • Vaccines
  • 14:30 NOVEL APPROACH TO PRESERVING LONGEVITY OF NEW AND CURRENT BETA-LACTAM ANTIBIOTICS

    Dr Betsy Abraham-Van Parijs

    Dr Betsy Abraham-Van Parijs, Senior Director, Infectious Diseases Medicine Development Centre, GlaxoSmithKline

    Nora Kaarela

    Nora Kaarela, Chief Executive Officer, IPSAT Therapies

    15:10 NEW METHODS FOR NOVEL ANTIBIOTIC DISCOVERY

    Dr Jeff Hermes

    Dr Jeff Hermes, Senior Director, Infectious Disease Research, Merck and Co

  • Established antibiotics use limited number of mechanisms                     
  • New structural classes addressing unexploited targets are urgently needed                    
  • Novel screening approaches are key
  • Discovery of platensimycin                     
  • Future direction           
  • 15:50 Afternoon Tea

    16:10 UPDATE GLYCYLCYCLINES - A NEW CLASS OF ANTIBIOTIC

    Dr E David G Macintosh

    Dr E David G Macintosh, Medical Director Infectious Diseases, Wyeth Europa

  • What progress has been made
  • Launch
  • Industry advancements
  • Target use and possible opportunities for disease/infection control
  • Insight into clinical trial results
  • 16:50 AR-709: A NOVEL ANTIBIOTIC DESIGNED TO OVERCOME RESISTANCE IN STREPTOCOCCI

    Dr Stephen Hawser

    Dr Stephen Hawser, Director Microbiology, Arpida

  • Rising drug resistance in streptococci and medical needs
  • Developing new drugs for streptococcal targeted therapy
  • DHFR, an under-exploited antibacterial target
  • Discovery of novel anti-streptococcal diaminopyrimidines
  • Clinical candidate AR-709

  • 17:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Professor Ian Chopra

    Professor Ian Chopra, Professor of Microbiology, Institute of Molecular & Cellular Biology, University of Leeds

    9:10 MRSA PREVALENCE AND TREATMENT

    Ron Van Amsterdam

    Ron Van Amsterdam, Senior Clinical Research Manager, Astellas Pharma Europe

  • Epidemiologic aspects
  • Current care and needs
  • Future therapeutic options
  • 9:50 DEVICE-RELATED INFECTIONS

    William Weiss

    William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals

  • Scope of infected devices
  • Problems associated with treatment
  • In vitro / In vivo models of device infections
  • Current therapy
  • New and emerging agents
  • 10:30 COMBINATION ANTIFUNGALS

    Dr Nafsika Georgopapadakou

    Dr Nafsika Georgopapadakou, Vice President, Infectious Diseases, MethylGene

    11:10 Morning Coffee

    11:30 CHEMICAL POST-EVOLUTION OF ANTIBACTERIAL NATURAL PRODUCTS

    Dr Dieter Haebich

    Dr Dieter Haebich, Director, Medicinal Chemistry, Bayer Healthcare A G

  •  Examining lead structure variants
  • Structural and Physiochemical requirements for antibacterial activity
  • 12:10 ANTIBACTERIAL AND ANTIFUNGAL DRUG RESISTANCE

    Dr Neil S Ryder

    Dr Neil S Ryder, Executive Director, Infectious Diseases, Novartis

  • Basic mechanisms of resistance, common features and differences between bacteria and fungi
  • Impact of resistance on selection of drug targets, with some recent examples
  • What can antifungal and antibacterial drug discovery learn from each other
  • 12:50 Networking Lunch

    13:50 NOVEL ß-LACTAM ANTIBIOTICS AND INHIBITOR COMBINATIONS

    Professor Malcolm Page

    Professor Malcolm Page, Head, Biology, Basilea Pharmaceutica

    Rising drug-resistance in Gram-negative bacteria, especially Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter species
    ß-Lactam resistance in Gram-negative bacteria
    ß-Lactamase inhibitors
    ß-Lactams with enhanced stability towards ß-lactamases
    New ß-lactam combinations with activity against "pan-resistant" Gram-negative pathogens

    14:30 CDI-936

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Research, Prolysis

  • New class of antibacterial
  • Potent against MRSA & MRSE clinical isolates
  • Efficacious in animal models
  • 15:10 Afternoon Tea

    15:30 DISCOVERY OF NEW ANTIVIRULENCE DRUGS

    Alexis Denis

    Alexis Denis, Vice President, Director, Medicinal Chemistry, Mutabilis

  • Antivirulence

  •  New antibacterial paradigm

  • New mechanism of action

  • Drug Discovery

  •  Innate Immunity

  • 16:10 THE USE OF MODIFIED ANTIMICROBIALS PEPTIDES AS ANTIBIOTICS

    Dr Søren Kjaerulff

    Dr Søren Kjaerulff, Director, Antimicrobials Peptides, Molecular Biotechnology, R&D, Novozymes

  • Update of Plectasin, a new antibiotic for treatment of resistant       Gram positive bacterial infections
  • Plectasin - the first Defensin from microorganisms
  • New class of antibacterials
  • Preclinical lead candidate
  • Gram positive activity incl. MRSA, VRSA & PRSP
  • New AMPs for Gram negative bacterial and fungal infections
  • 16:50 ANTIBIOTICS TARGETING THE RIBOZYME

    Dr Joyce Sutcliffe

    Dr Joyce Sutcliffe, Chief Research Scientist, Rib-X Pharmaceuticals

  • The 50S ribosomal subunit provides multiple antibacterial target sites
  • 3D knowledge provides insight for circumventing target-based resistance
  • Use of proprietary gram-positive 50S structure yields important understanding for drug design
  • SBDD enrichment for drug-like properties and good binding before compounds are synthesized
  • Rib-X approach yields distinct antibiotic classes for different market segments
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Optimising development in the anti-infectives market
    Workshop

    Optimising development in the anti-infectives market

    Crowne Plaza Hotel - The City
    25th April 2007
    London, United Kingdom

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.